1
Regression of Mantle Cell Lymphoma Involving the Stomach Before CAR-T cells Day 29 after CAR-T cells Regression of Diffuse B Cell Lymphoma Before CAR-T cells Day 32 after CAR-T cells Tumor regressions observed in Phase 1/2 clinical trials for patients with B-cell cancers after infusion of CAR (Chimeric Antigen Receptor) T cells engineered at Fred Hutch. The next pillar of cancer therapy TUMOR-MELTING T CELLS Chimeric Antigen Receptor T CELL Schematic of a CAR-T cell Regression of Advanced Acute Leukemia Involving Bone Marrow and Kidneys Before CAR-T cells Day 37 after CAR-T cells Bone Marrow (Before CAR-T cells) 83.6% blasts Bone Marrow (Day 28 after CAR-T cells) Complete remission Scapular lesion Para-aortic tumor Retroperitoneal Iliac tumor Regression of Extramedullary Acute Leukemia Before CAR-T cells Day 31 after CAR-T cells Before CAR-T cells Day 30 after CAR-T cells Day 60 after CAR-T cells Regression of B Cell Lymphoma Involving the Kidney Source: Riddell, Turtle and Maloney Labs, Fred Hutchinson Cancer Research Center
![Engineering better chimeric antigen receptor T cells · 2020. 12. 2. · Mata et al()45] Collinson-Pautz ... IL-7/CCL19 Improves the infiltration and anti-tumor response of both](https://static.documents.pub/doc/80x56/61016484b886dd17e2043354/engineering-better-chimeric-antigen-receptor-t-cells-2020-12-2-mata-et-al45.jpg)
![Targeting B7-H3 via chimeric antigen receptor T cells and ......response rates [8]. Multiple factors, including T-cell inl-tration, neoantigen burden and tumor metabolism, are involved](https://static.documents.pub/doc/80x56/61179915f32005778009addb/targeting-b7-h3-via-chimeric-antigen-receptor-t-cells-and-response-rates.jpg)
